

Henk-Jan Guchelaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5786549/publications.pdf>

Version: 2024-02-01

368
papers

18,310
citations

17405

63
h-index

19136

118
g-index

373
all docs

373
docs citations

373
times ranked

23907
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	13.7	1,974
2	Pharmacogenetics: From Bench to Byte” An Update of Guidelines. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 662-673.	2.3	869
3	Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 171-179.	1.3	617
4	The Risk of Cancer in Users of Statins. <i>Journal of Clinical Oncology</i> , 2004, 22, 2388-2394.	0.8	475
5	Clinical pharmacokinetics of tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2009, 35, 692-706.	3.4	437
6	Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. <i>Clinical and Translational Science</i> , 2020, 13, 116-124.	1.5	353
7	Cardiotoxicity of cytotoxic drugs. <i>Cancer Treatment Reviews</i> , 2004, 30, 181-191.	3.4	318
8	Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 609-641.	3.4	270
9	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 770-777.	2.3	244
10	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 341-358.	2.3	240
11	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , The, 2018, 19, 1459-1467.	5.1	238
12	Pharmacogenetics: From Bench to Byte. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 781-787.	2.3	229
13	A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1765-1775.	6.7	225
14	Liposomal drug formulations in cancer therapy: 15 years along the road. <i>Drug Discovery Today</i> , 2012, 17, 160-166.	3.2	220
15	Making sense of big data in health research: Towards an EU action plan. <i>Genome Medicine</i> , 2016, 8, 71.	3.6	190
16	Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. <i>Arthritis and Rheumatism</i> , 2006, 54, 1087-1095.	6.7	188
17	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 599-618.	2.3	186
18	Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 4406-4412.	0.8	177

#	ARTICLE	IF	CITATIONS
19	Translating Pharmacogenomics: Challenges on the Road to the Clinic. <i>PLoS Medicine</i> , 2007, 4, e209.	3.9	174
20	Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 907-917.e7.	0.6	169
21	Relationship between Single Nucleotide Polymorphisms and Haplotypes in <i>DPYD</i> and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3455-3468.	3.2	168
22	Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2423-2429.	0.8	150
23	Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. <i>Clinical Cancer Research</i> , 2011, 17, 620-629.	3.2	150
24	Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. <i>Supportive Care in Cancer</i> , 1997, 5, 281-288.	1.0	147
25	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
26	Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. <i>Investigational New Drugs</i> , 2013, 31, 1087-1094.	1.2	133
27	Histone deacetylase inhibitors. <i>Anti-Cancer Drugs</i> , 2014, 25, 140-149.	0.7	130
28	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <i>European Journal of Human Genetics</i> , 2020, 28, 508-517.	1.4	127
29	Quantitative determination of the macrolide antibiotics erythromycin, roxithromycin, azithromycin and clarithromycin in human serum by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. <i>Biomedical Applications</i> . 1998, 720, 89-97.	1.7	125
30	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2830-2839.	6.7	123
31	Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 187-197.	1.0	119
32	Effect of Milk Thistle (<i>Silybum marianum</i>) on the Pharmacokinetics of Irinotecan. <i>Clinical Cancer Research</i> , 2005, 11, 7800-7806.	3.2	115
33	Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 46-51.	6.7	111
34	Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2016, 54, 40-48.	1.3	110
35	Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib. <i>Clinical Cancer Research</i> , 2007, 13, 7394-7400.	3.2	107
36	Sirolimus and everolimus in kidney transplantation. <i>Drug Discovery Today</i> , 2015, 20, 1243-1249.	3.2	101

#	ARTICLE	IF	CITATIONS
37	Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review. <i>Cancer Treatment Reviews</i> , 2015, 41, 935-950.	3.4	101
38	Mitotane has a strong and a durable inducing effect on CYP3A4 activity. <i>European Journal of Endocrinology</i> , 2011, 164, 621-626.	1.9	99
39	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1375-1381.	0.5	94
40	Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab. <i>Clinical Cancer Research</i> , 2011, 17, 5668-5673.	3.2	91
41	A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 720-737.	1.3	90
42	Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. <i>Oncologist</i> , 2011, 16, 1239-1249.	1.9	85
43	Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2890.	1.0	84
44	Clinical and pharmacogenetic factors associated with irinotecan toxicity. <i>Cancer Treatment Reviews</i> , 2008, 34, 656-669.	3.4	82
45	Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer. <i>Clinical Therapeutics</i> , 2013, 35, 1946-1954.	1.1	81
46	Translating <i>DPYD</i> genotype into DPD phenotype: using the <i>DPYD</i> gene activity score. <i>Pharmacogenomics</i> , 2015, 16, 1275-1284.	0.6	81
47	Glutathione S-transferase Polymorphisms Are Not Associated With Population Pharmacokinetic Parameters of Busulfan in Pediatric Patients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 504-510.	1.0	79
48	The role of pharmacogenetics in capecitabine efficacy and toxicity. <i>Cancer Treatment Reviews</i> , 2016, 50, 9-22.	3.4	77
49	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2010, 46, 1829-1834.	1.3	75
50	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 621-629.	0.9	75
51	Clinical Implications of <i>CYP2D6</i> Genotyping in Tamoxifen Treatment for Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 15-21.	3.2	74
52	Apoptosis: molecular mechanisms and implications for cancer chemotherapy. <i>International Journal of Clinical Pharmacy</i> , 1997, 19, 119-125.	1.4	73
53	Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. <i>Annals of Oncology</i> , 2009, 20, 358-364.	0.6	73
54	Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1247-1252.	0.8	73

#	ARTICLE	IF	CITATIONS
55	Development of the <sc>PG</sc>â€œPassport: A Panel of Actionable Germline Genetic Variants for Preâ€œmptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 866-873.	2.3	73
56	Individualized dosing of tyrosine kinase inhibitors: are we there yet?. <i>Drug Discovery Today</i> , 2015, 20, 18-36.	3.2	72
57	Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 636-646.	0.8	72
58	A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 937, 33-43.	1.2	71
59	Pharmacogenetic Information in Clinical Guidelines: The European Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 795-801.	2.3	71
60	Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2889-2902.	1.1	70
61	Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014, 3, 1-12.	1.3	69
62	Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. <i>Human Mutation</i> , 2017, 38, 310-316.	1.1	69
63	Flucytosine: Correlation between Toxicity and Pharmacokinetic Parameters. <i>Chemotherapy</i> , 2000, 46, 86-94.	0.8	68
64	A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. <i>European Heart Journal</i> , 2012, 33, 165-175.	1.0	68
65	Lapatinib for Advanced or Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 536-542.	1.9	67
66	Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 893-898.	2.2	67
67	Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. <i>Haematologica</i> , 2010, 95, 1943-1951.	1.7	66
68	A cost analysis of upfront DPYD genotypeâ€œguided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	1.3	65
69	Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: A review. <i>Clinical Oncology</i> , 1994, 6, 40-48.	0.6	64
70	Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. <i>Pharmacogenomics</i> , 2010, 11, 163-175.	0.6	64
71	Impact of<i>ABCG2</i> polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2011, 12, 159-170.	0.6	63
72	Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2012, 51, 467-480.	1.6	63

#	ARTICLE	IF	CITATIONS
73	Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 77-83.	1.1	61
74	Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 523-536.	1.3	60
75	Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. <i>Drug Discovery Today</i> , 2014, 19, 1572-1586.	3.2	58
76	The role of pharmacogenetics in the treatment of osteosarcoma. <i>Drug Discovery Today</i> , 2016, 21, 1775-1786.	3.2	58
77	Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. <i>Genes</i> , 2019, 10, 416.	1.0	58
78	Exploratory analysis of four polymorphisms in humanGGHandFPGSGenes and their effect in methotrexate-treated rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2007, 8, 141-150.	0.6	57
79	Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. <i>Drug Discovery Today</i> , 2007, 12, 125-131.	3.2	57
80	Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. <i>BMC Medicine</i> , 2019, 17, 110.	2.3	56
81	Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2525.	1.8	55
82	CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 20, 451-457.	1.9	53
83	Low literacy and written drug information: information-seeking, leaflet evaluation and preferences, and roles for images. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 1372-1379.	1.0	53
84	A Single Oral Dose of Thalidomide Enhances the Capacity of Lymphocytes to Secrete Gamma Interferon in Healthy Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2286-2290.	1.4	52
85	Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2009, 45, 572-578.	1.3	52
86	Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 175-184.	0.6	52
87	Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 935-944.	0.7	51
88	Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. <i>International Journal of Clinical Pharmacy</i> , 2011, 33, 33-43.	1.0	51
89	Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 204-209.	0.9	51
90	Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. <i>Clinical Cancer Research</i> , 2018, 24, 2312-2318.	3.2	51

#	ARTICLE	IF	CITATIONS
91	Acute Effects of High-Dose Furosemide on Residual Renal Function in CAPD Patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 339-347.	1.1	51
92	Influence of the d3-Growth Hormone (GH) Receptor Isoform on Short-Term and Long-Term Treatment Response to GH Replacement in GH-Deficient Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2828-2834.	1.8	49
93	Medication Errors. <i>Drugs</i> , 2005, 65, 1735-1746.	4.9	48
94	Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 331-338.	1.0	48
95	Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts. <i>PLoS ONE</i> , 2014, 9, e115869.	1.1	47
96	Pharmacogenetics of EGFR and VEGF inhibition. <i>Drug Discovery Today</i> , 2007, 12, 1054-1060.	3.2	46
97	Preventing adverse drug events in hospital practice: an overview. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 1129-1135.	0.9	45
98	Marginal increase of sunitinib exposure by grapefruit juice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 695-703.	1.1	45
99	Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 519-529.	0.6	45
100	Non-Steroidal Anti-Inflammatory Drugs and Melanoma Risk: Large Dutch Population-Based Caseâ€“Control Study. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2620-2627.	0.3	43
101	Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 163-174.	0.8	43
102	Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1589-1598.	0.8	43
103	Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-8.	0.6	42
104	Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 243-247.	0.7	42
105	Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	42
106	Acute effects of high-dose furosemide on residual renal function in CAPD patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 339-47.	1.1	41
107	A nationwide survey of pharmacistsâ€™ perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. <i>Pharmacogenomics</i> , 2017, 18, 215-225.	0.6	40
108	Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2011, 22, 1147-1153.	0.6	39

#	ARTICLE	IF	CITATIONS
109	The extent and effects of patient involvement in pictogram design for written drug information: a short systematic review. <i>Drug Discovery Today</i> , 2018, 23, 1312-1318.	3.2	39
110	Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?. <i>European Journal of Cancer</i> , 2007, 43, 2580-2589.	1.3	38
111	Therapeutic modulation of k-ras signaling in colorectal cancer. <i>Drug Discovery Today</i> , 2010, 15, 502-516.	3.2	38
112	Simultaneous Isolation of CD8+ and CD4+ T Cells Specific for Multiple Viruses for Broad Antiviral Immune Reconstitution After Allogeneic Stem Cell Transplantation. <i>Journal of Immunotherapy</i> , 2011, 34, 307-319.	1.2	38
113	A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. <i>European Journal of Human Genetics</i> , 2019, 27, 1532-1541.	1.4	38
114	Quantitative determination of melatonin in human plasma and cerebrospinal fluid with high-performance liquid chromatography and fluorescence detection. <i>Biomedical Chromatography</i> , 2000, 14, 306-310.	0.8	37
115	Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time. <i>European Journal of Cancer</i> , 2020, 141, 9-20.	1.3	37
116	Technologies for Pharmacogenomics: A Review. <i>Genes</i> , 2020, 11, 1456.	1.0	37
117	Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 591-604.	2.3	37
118	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. <i>European Journal of Human Genetics</i> , 2022, 30, 1114-1120.	1.4	37
119	Application of the Bow-Tie Model in Medication Safety Risk Analysis. <i>Drug Safety</i> , 2009, 32, 663-673.	1.4	36
120	Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 310-313.	1.1	35
121	Clinical development of gene- and cell-based therapies: overview of the European landscape. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16073.	1.8	35
122	Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 391-402.	1.9	35
123	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. <i>PLoS ONE</i> , 2014, 9, e87645.	1.1	34
124	Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 465-472.	1.0	34
125	Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 599-606.	1.1	34
126	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 3436-3441.	3.2	34

#	ARTICLE	IF	CITATIONS
127	Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. <i>Cytotherapy</i> , 2016, 18, 797-805.	0.3	34
128	Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1335-1342.	2.9	34
129	Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 63-71.	1.1	34
130	Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. <i>Pharmacogenomics</i> , 2012, 13, 1087-1094.	0.6	33
131	High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric <sc>HSCT</sc>: a prospective multicentre study. <i>British Journal of Haematology</i> , 2017, 179, 772-780.	1.2	33
132	Implementation of Pharmacogenomics in Everyday Clinical Settings. <i>Advances in Pharmacology</i> , 2018, 83, 219-246.	1.2	33
133	Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 363-370.	0.8	32
134	Effect of genetic variants <i>GSTA1</i> and <i>CYP39A1</i> and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Pharmacogenomics</i> , 2013, 14, 1683-1690.	0.6	32
135	Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 62-68.	2.3	32
136	Implementation of a computerized physician medication order entry system at the Academic Medical Centre in Amsterdam. <i>International Journal of Clinical Pharmacy</i> , 2003, 25, 88-93.	1.4	31
137	Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1168-1176.	0.6	31
138	Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal <sc>TPMT</sc> genotype. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 953-963.	1.9	31
139	Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study. <i>PLoS ONE</i> , 2014, 9, e112201.	1.1	31
140	Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection. <i>Biomedical Applications</i> , 1999, 734, 203-210.	1.7	30
141	Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS. <i>Journal of the Neurological Sciences</i> , 2001, 191, 121-125.	0.3	30
142	Genotyping of DNA Samples Isolated from Formalin-Fixed Paraffin-Embedded Tissues Using Pre-amplification. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 746-749.	1.2	30
143	Insulin-like growth factor 1 receptor expression and IGF1R 3129G>&T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOC 2010-01). <i>Breast Cancer Research</i> , 2016, 18, 3.	2.2	30
144	The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1998, 44, 293-293.	2.8	29

#	ARTICLE	IF	CITATIONS
145	Liquid Chromatography-Tandem Mass Spectrometry Outperforms Fluorescence Polarization Immunoassay in Monitoring Everolimus Therapy in Renal Transplantation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 413-419.	1.0	29
146	Explaining variability in ciclosporin exposure in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 579-590.	0.8	29
147	Liver and kidney function in patients with Covid-19 treated with remdesivir. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4450-4454.	1.1	29
148	Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping. , 1999, 13, 309-314.		28
149	Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. <i>Anti-Cancer Drugs</i> , 2006, 17, 1099-1105.	0.7	28
150	A Computerized Adverse Drug Event Alerting System Using Clinical Rules. <i>Drug Safety</i> , 2011, 34, 233-242.	1.4	28
151	Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines. <i>Frontiers in Pharmacology</i> , 2020, 11, 567048.	1.6	28
152	Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. <i>International Journal of Clinical Pharmacy</i> , 2004, 26, 191-192.	1.4	27
153	Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1245-1251.	0.8	27
154	The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs. <i>Clinical Pharmacokinetics</i> , 2013, 52, 833-854.	1.6	27
155	Evaluation of rule effectiveness and positive predictive value of clinical rules in a Dutch clinical decision support system in daily hospital pharmacy practice. <i>Artificial Intelligence in Medicine</i> , 2013, 59, 15-21.	3.8	27
156	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 2882-2888.	0.8	27
157	Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2183-2187.	0.5	27
158	Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy. <i>Anesthesia and Analgesia</i> , 2016, 123, 587-596.	1.1	27
159	Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. <i>Acta Oncologica</i> , 2017, 56, 582-589.	0.8	27
160	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 162, 148-157.	1.3	27
161	Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity. <i>Current Cancer Drug Targets</i> , 2007, 7, 504-509.	0.8	26
162	Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. <i>Pharmacogenomics</i> , 2013, 14, 2005-2012.	0.6	26

#	ARTICLE	IF	CITATIONS
163	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1344-1350.	1.0	26
164	<i>FCGR2B</i> genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2015, 16, 373-381.	0.6	26
165	Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2015, 33, 1242-1247.	1.2	26
166	Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 553-561.	1.1	26
167	Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2761-2769.	1.1	26
168	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144.	0.7	26
169	Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021, 12, 693453.	1.6	26
170	Population Pharmacokinetics of Flucytosine: Comparison and Validation of Three Models Using STS, NPEM, and NONMEM. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 676-687.	1.0	25
171	Co-ordinated isolation of CD8+ and CD4+ T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. <i>Cytotherapy</i> , 2010, 12, 933-944.	0.3	25
172	Development of cell therapy medicinal products by academic institutes. <i>Drug Discovery Today</i> , 2016, 21, 1206-1212.	3.2	25
173	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and <i>CD39</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
174	Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1437-1444.	0.8	24
175	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013, 45, 468-469.	9.4	24
176	Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 87-96.	1.1	24
177	Evaluation of clinical implementation of prospective <i>DPYD</i> genotyping in 5-fluorouracil- or capecitabine-treated patients. <i>Pharmacogenomics</i> , 2016, 17, 721-729.	0.6	24
178	Pharmaceutical pictograms for low-literate patients: Understanding, risk of false confidence, and evidence-based design strategies. <i>Patient Education and Counseling</i> , 2017, 100, 966-973.	1.0	24
179	EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. <i>Drug Discovery Today</i> , 2018, 23, 1328-1333.	3.2	24
180	Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 617-627.	2.3	24

#	ARTICLE	IF	CITATIONS
181	A brighter future for the implementation of pharmacogenomic testing. <i>European Journal of Human Genetics</i> , 2016, 24, 1658-1660.	1.4	23
182	More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1873-1881.	0.9	23
183	A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. <i>Cytotherapy</i> , 2018, 20, 769-778.	0.3	23
184	Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. <i>European Journal of Cancer</i> , 2007, 43, 459-465.	1.3	22
185	Effect of <i>CYP2C9</i> polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. <i>Pharmacogenomics</i> , 2010, 11, 1517-1523.	0.6	22
186	Development of a Pharmacokinetic Model of Mitotane. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 58-65.	1.0	22
187	Genetic polymorphisms of 3' untranslated region of <i>SULT1A1</i> and their impact on tamoxifen metabolism and efficacy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 401-411.	1.1	22
188	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between <i>CYP2D6</i> and opioids (codeine, tramadol and oxycodone). <i>European Journal of Human Genetics</i> , 2022, 30, 1105-1113.	1.4	22
189	Simultaneous determination of clozapine, norclozapine and clozapine-N-oxide in human plasma by high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Chromatography</i> , 2001, 15, 280-286.	0.8	21
190	Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. <i>Pharmacogenomics</i> , 2007, 8, 159-176.	0.6	21
191	Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cancer Epidemiology</i> , 2009, 33, 391-395.	0.8	21
192	Impact of Chemotherapy-Induced Nausea and Vomiting on Quality of Life in Indonesian Patients With Gynecologic Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 139-145.	1.2	21
193	Sunitinib-induced hypertension in <i>CYP3A4</i> rs4646437 A-allele carriers with metastatic renal cell carcinoma. <i>Pharmacogenomics Journal</i> , 2017, 17, 42-46.	0.9	21
194	A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis. <i>Biomedical Chromatography</i> , 2004, 18, 723-726.	0.8	20
195	Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC. <i>Clinical Cancer Research</i> , 2008, 14, 8308-8313.	3.2	20
196	Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 604-613.	1.3	20
197	Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework. <i>Journal of Clinical Medicine</i> , 2020, 9, 814.	1.0	20
198	RAINFOREST: a random forest approach to predict treatment benefit in data from (failed) clinical drug trials. <i>Bioinformatics</i> , 2020, 36, i601-i609.	1.8	20

#	ARTICLE	IF	CITATIONS
199	3D Printing of Pediatric Medication: The End of Bad Tasting Oral Liquids?â€”A Scoping Review. <i>Pharmaceutics</i> , 2022, 14, 416.	2.0	20
200	Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. <i>PLoS ONE</i> , 2022, 17, e0268534.	1.1	20
201	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1477-1484.	0.8	19
202	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 605-618.	1.5	19
203	The effect of rs5758550 on <i>CYP2D6</i> phenotype and formation of endoxifen in breast cancer patients using tamoxifen. <i>Pharmacogenomics</i> , 2017, 18, 1125-1132.	0.6	19
204	The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen. <i>Pharmacogenomics</i> , 2017, 18, 1041-1045.	0.6	19
205	Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 838-845.	0.6	19
206	An Electronic Health Record Text Mining Tool to Collect Real-World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 644-652.	2.3	19
207	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. <i>Pharmacogenomics</i> , 2013, 14, 63-73.	0.6	18
208	Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1197-1210.	0.9	17
209	Pharmacogenetics in Oncology: A Promising Field. <i>Current Pharmaceutical Design</i> , 2010, 16, 155-163.	0.9	17
210	Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. <i>Investigational New Drugs</i> , 2011, 29, 137-143.	1.2	17
211	Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 675-683.	0.7	17
212	Non-Homologous End-Joining Pathway Associated with Occurrence of Myocardial Infarction: Gene Set Analysis of Genome-Wide Association Study Data. <i>PLoS ONE</i> , 2013, 8, e56262.	1.1	17
213	Patients' preferences for visuals: Differences in the preferred level of detail, type of background and type of frame of icons depicting organs between literate and low-literate people. <i>Patient Education and Counseling</i> , 2015, 98, 226-233.	1.0	17
214	Estimating the potential impact of implementing preemptive pharmacogenetic testing in primary care across the UK. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2907-2925.	1.1	17
215	3D printed furosemide and sildenafil tablets: Innovative production and quality control. <i>International Journal of Pharmaceutics</i> , 2021, 603, 120694.	2.6	17
216	Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. <i>Pharmacogenomics Journal</i> , 2022, 22, 75-81.	0.9	17

#	ARTICLE	IF	CITATIONS
217	The potential role of computerisation and information technology in improving prescribing in hospitals. <i>International Journal of Clinical Pharmacy</i> , 2003, 25, 83-87.	1.4	16
218	Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. <i>Investigational New Drugs</i> , 2011, 29, 953-962.	1.2	16
219	A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands. <i>Pharmacogenomics</i> , 2018, 19, 311-319.	0.6	16
220	Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Anti-Cancer Drugs</i> , 2015, 26, 872-877.	0.7	15
221	Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. <i>Pharmacological Research</i> , 2018, 128, 122-129.	3.1	15
222	Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 99.e1-99.e7.	0.6	15
223	Are Angiotensin II Receptor Antagonists Safe in Patients With Previous Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema?. <i>Hypertension</i> , 2001, 37, E1.	1.3	14
224	5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 39-47.	1.0	14
225	Risk assessment in clinical pharmacy. <i>International Journal of Clinical Pharmacy</i> , 2003, 25, 98-103.	1.4	14
226	Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next-Generation Sequencing. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 383-385.	2.3	14
227	High-Quality Genotyping Data from Formalin-Fixed, Paraffin-Embedded Tissue on the Drug Metabolizing Enzymes and Transporters Plus Array. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 4-9.	1.2	14
228	Population pharmacokinetics of lenalidomide in multiple myeloma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 189-200.	1.1	14
229	Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression. <i>Scientific Reports</i> , 2018, 8, 5250.	1.6	14
230	Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer. <i>Clinical Pharmacokinetics</i> , 2018, 57, 455-473.	1.6	14
231	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. <i>European Journal of Cancer</i> , 2018, 104, 210-218.	1.3	14
232	Simultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography. <i>Biomedical Chromatography</i> , 2001, 15, 89-94.	0.8	13
233	Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats. <i>Archives of Toxicology</i> , 2005, 79, 268-276.	1.9	13
234	Genetic markers of treatment response in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2006, 8, 369-377.	2.1	13

#	ARTICLE	IF	CITATIONS
235	Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle. <i>Pharmacogenomics</i> , 2010, 11, 1011-1017.	0.6	13
236	Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 83-88.	0.8	13
237	Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring. <i>European Journal of Endocrinology</i> , 2014, 171, 677-683.	1.9	13
238	CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 171-179.	1.1	13
239	The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 501-507.	1.0	13
240	Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0131091.	1.1	13
241	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. <i>European Journal of Cancer</i> , 2017, 86, 226-232.	1.3	13
242	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2019, 20, 85-93.	0.6	13
243	Individualization of cancer therapy based on cytochrome P450 polymorphism: a pharmacogenetic approach. <i>Cancer Treatment Reviews</i> , 1997, 23, 321-339.	3.4	12
244	Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 355-362.	1.0	12
245	Perinatal dioxin exposure, cytochrome P-450 activity, liver functions and thyroid hormones at follow-up after 7-12 years. <i>Chemosphere</i> , 2008, 70, 1865-1872.	4.2	12
246	Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1303-1306.	1.1	12
247	A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1575-1586.	1.1	12
248	Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2033-2044.	1.1	12
249	Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. <i>Drug Discovery Today</i> , 2021, 26, 2527-2546.	3.2	12
250	Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 181-187.	0.8	11
251	Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1021-1026.	0.8	11
252	Use of plasmid-derived external quality control samples in pharmacogenetic testing. <i>Pharmacogenomics</i> , 2008, 9, 1261-1266.	0.6	11

#	ARTICLE	IF	CITATIONS
253	Pharmacogenetics in chemotherapy of colorectal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2009, 23, 257-273.	1.0	11
254	Genetic Factors Are Relevant and Independent Determinants of Antihypertensive Drug Effects in a Multiracial Population. <i>American Journal of Hypertension</i> , 2009, 22, 1295-1302.	1.0	11
255	Detailed Analysis of IFN γ Response Upon Activation Permits Efficient Isolation of Cytomegalovirus-specific CD8+ T Cells for Adoptive Immunotherapy. <i>Journal of Immunotherapy</i> , 2009, 32, 513-523.	1.2	11
256	Novel insights in pharmacogenetics of drug response in Parkinson's disease. <i>Pharmacogenomics</i> , 2010, 11, 127-129.	0.6	11
257	The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. <i>European Journal of Internal Medicine</i> , 2010, 21, 293-296.	1.0	11
258	Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2014, 759, 37-44.	0.4	11
259	Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 227-237.	1.1	11
260	Medication error due to ambiguous labelling of a commercial product. <i>International Journal of Clinical Pharmacy</i> , 2004, 26, 10-11.	1.4	10
261	Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. <i>Annals of Oncology</i> , 2012, 23, 3091-3097.	0.6	10
262	Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 429-433.	1.1	10
263	Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 167-173.	0.8	10
264	Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. <i>Genes</i> , 2018, 9, 585.	1.0	10
265	Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 179-182.	1.1	10
266	Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review. <i>Pharmacogenomics Journal</i> , 2020, 20, 159-168.	0.9	10
267	Exposure-response analysis of endoxifen serum concentrations in early-breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1141-1152.	1.1	10
268	Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. <i>Scientific Reports</i> , 2021, 11, 415.	1.6	10
269	An accelerated stability study of 5-flucytosine in intravenous solution. <i>International Journal of Clinical Pharmacy</i> , 1999, 21, 35-39.	1.4	9
270	Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. <i>Drug Discovery Today</i> , 2009, 14, 837-844.	3.2	9

#	ARTICLE	IF	CITATIONS
271	GenoChip CYP2D6 macroarray as a method to genotype for <i>CYP2D6</i> variants: results of a validation study in a Caucasian population. <i>Pharmacogenomics</i> , 2015, 16, 681-687.	0.6	9
272	Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancerâ€™Genetic- and tumor-related biomarkers for response and toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 529.e9-529.e16.	0.8	9
273	The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine. <i>Pharmacogenomics Journal</i> , 2018, 18, 160-166.	0.9	9
274	Adverse drug reactions on sexual functioning: a systematic overview. <i>Drug Discovery Today</i> , 2019, 24, 890-897.	3.2	9
275	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. <i>Pharmacogenomics Journal</i> , 2019, 19, 473-479.	0.9	9
276	Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 116-120.	1.0	9
277	Substrate specificity of CYP2D6 genetic variants. <i>Pharmacogenomics</i> , 2021, 22, 1081-1089.	0.6	9
278	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 231-247.	1.6	9
279	Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?. <i>Frontiers in Pharmacology</i> , 2022, 13, 826004.	1.6	9
280	Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
281	Multiplex Pyrosequencing of Two Polymorphisms in DNA Repair Gene XRCC1. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 444-448.	1.2	8
282	Phenotyping drug disposition in oncology. <i>Cancer Treatment Reviews</i> , 2012, 38, 715-725.	3.4	8
283	Pharmacogenetic biomarkers for predicting drug response. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 723-735.	1.5	8
284	Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	8
285	Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib. <i>Pharmacogenomics Journal</i> , 2018, 18, 49-55.	0.9	8
286	Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands. <i>Frontiers in Pharmacology</i> , 2022, 13, 803935.	1.6	8
287	Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production. <i>Fundamental and Clinical Pharmacology</i> , 2001, 15, 419-424.	1.0	7
288	The Dutch Vision of Clinical Pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 366-368.	2.3	7

#	ARTICLE	IF	CITATIONS
289	Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 461-468.	0.7	7
290	Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1 β gene. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 279-84.	1.4	7
291	Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 47-52.	1.1	7
292	Understanding clinical development of chimeric antigen receptor T cell therapies. <i>Cytotherapy</i> , 2017, 19, 703-709.	0.3	7
293	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2350-2356.	3.2	7
294	Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. <i>PLoS ONE</i> , 2018, 13, e0208080.	1.1	7
295	Pharmacogenomics, a novel section in the European Journal of Human Genetics. <i>European Journal of Human Genetics</i> , 2018, 26, 1399-1400.	1.4	7
296	The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples. <i>Scientific Reports</i> , 2019, 9, 2495.	1.6	7
297	A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. <i>Biomedical Chromatography</i> , 2020, 34, e4732.	0.8	7
298	Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities. <i>Frontiers in Pharmacology</i> , 2020, 11, 1241.	1.6	7
299	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 191-203.	1.6	7
300	Cost-Benefit Analysis of Vaccination Against Influenza of Employees from an Academic Medical Centre. <i>Disease Management and Health Outcomes</i> , 2002, 10, 579-587.	0.3	6
301	Is rectal administration an alternative route for imatinib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 623-624.	1.1	6
302	Pharmacogenetics of taste: turning bitter pills sweet?. <i>Pharmacogenomics</i> , 2014, 15, 111-119.	0.6	6
303	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2017, 18, 945-953.	0.6	6
304	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021, 60, 89-102.	1.6	6
305	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 1204-1212.	0.8	6
306	Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiological study. <i>Journal of Clinical Oncology</i> , 2009, 27, CRA509-CRA509.	0.8	6

#	ARTICLE	IF	CITATIONS
307	Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2007, 31, 1545-1551.	0.4	5
308	Breath Tests to Phenotype Drug Disposition in Oncology. <i>Clinical Pharmacokinetics</i> , 2013, 52, 919-926.	1.6	5
309	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 227-231.	0.7	5
310	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1201-1215.	1.6	5
311	A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 631-635.	0.7	4
312	Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 279-288.	0.7	4
313	Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia. <i>Pharmacogenomics</i> , 2015, 16, 1265-1274.	0.6	4
314	Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 577968.	1.6	4
315	Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1925-1931.	0.5	4
316	Prospective study evaluating the effect of impaired tamoxifen metabolism on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting. <i>Journal of Clinical Oncology</i> , 2016, 34, 523-523.	0.8	4
317	Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance. <i>Scientific Reports</i> , 2022, 12, 4206.	1.6	4
318	Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians. <i>International Journal of Biological Markers</i> , 2012, 27, 34-38.	0.7	3
319	The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 114, 24-29.	1.9	3
320	Detecting DPD deficiency: when perfect is the enemy of good. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 717-719.	1.1	3
321	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. <i>Mycoses</i> , 2021, 64, 1111-1116.	1.8	3
322	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan. <i>Journal of Clinical Oncology</i> , 2021, 39, 3574-3574.	0.8	3
323	Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study. <i>Journal of Clinical Oncology</i> , 2009, 27, CRA509-CRA509.	0.8	3
324	A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen. <i>Journal of Clinical Oncology</i> , 2018, 36, 523-523.	0.8	3

#	ARTICLE	IF	CITATIONS
325	Outcomes of an antimicrobial control program in a Dutch hospital. American Journal of Health-System Pharmacy, 2004, 61, 1702-1706.	0.5	2
326	Pharmacogenetics in Transplant Patients: Mind the Mix. Clinical Pharmacology and Therapeutics, 2013, 94, 443-444.	2.3	2
327	Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule. Internal and Emergency Medicine, 2014, 9, 481-482.	1.0	2
328	Pharmacogenetics in electroconvulsive therapy and adjunctive medications. Pharmacogenomics, 2015, 16, 1015-1031.	0.6	2
329	<i>SLC04A1</i>, <i>SLC22A2</i> and <i>SLC28A2</i> variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients. Pharmacogenomics, 2018, 19, 613-619.	0.6	2
330	Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety. Pharmacoepidemiology and Drug Safety, 2018, 27, 3-8.	0.9	2
331	Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al. Journal of Clinical Oncology, 2019, 37, 1984-1985.	0.8	2
332	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? â€œ Authors' reply. Lancet Oncology, The, 2019, 20, e67.	5.1	2
333	Confirmation practice in pharmacogenetic testing; how good is good enough?. Clinica Chimica Acta, 2019, 490, 77-80.	0.5	2
334	An estimation of patients at potential risk for drug-induced sexual dysfunction using pharmacy dispensing data. Family Practice, 2020, 38, 292-298.	0.8	2
335	Contribution of Common and Rare Genetic Variants in CEP72 on Vincristineâ€­induced Peripheral Neuropathy in Brain Tumor Patients. British Journal of Clinical Pharmacology, 2022, , .	1.1	2
336	The Potential Application of Extracellular Vesicles from Liquid Biopsies for Determination of Pharmacogene Expression. Pharmaceuticals, 2022, 15, 252.	1.7	2
337	Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury. Journal of Personalized Medicine, 2022, 12, 892.	1.1	2
338	A splinter. , 2001, 23, 123-123.		1
339	Formulation, Quality Control and Shelf Life of the Experimental Cytostatic Drug Cyclopentenyl Cytosine. Drug Development and Industrial Pharmacy, 2006, 32, 497-503.	0.9	1
340	Quantitative analysis of the experimental cytotoxic drug cyclopentenyl cytosine and its metabolite in plasma with HPLC tandem mass spectrometry. Biomedical Chromatography, 2008, 22, 1368-1373.	0.8	1
341	What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?. Pharmacogenomics, 2017, 18, 1-4.	0.6	1
342	Nonâ€­Cancer Drug Repurposing Candidates for Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2019, 25, 147-148.	1.0	1

#	ARTICLE	IF	CITATIONS
343	One non-believer: Response to "Obviously Nine Believers: Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing". <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 7-8.	1.2	1
344	Precision Medicine Using Pharmacogenomic Panel-Testing. <i>Advances in Molecular Pathology</i> , 2020, 3, 131-142.	0.2	1
345	Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool. <i>Scientific Reports</i> , 2021, 11, 19084.	1.6	1
346	CYP3A4 phenotyping with midazolam to predict sunitinib exposure.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2592-2592.	0.8	1
347	Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22152-e22152.	0.8	1
348	Learning From Consultations Conducted by Community Pharmacists in Northern Ireland for Nonprescription Sildenafil: A Qualitative Study Using the Theoretical Domains Framework. <i>Sexual Medicine</i> , 2021, 9, 100440-100440.	0.9	1
349	Toxicity and Effectivity of the Experimental Cytotoxic Drug Cyclopentenyl Cytosine in NOD/scid Mice with Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005, 106, 4574-4574.	0.6	1
350	Respiratory Adherence Care Enhancer Questionnaire: Identifying Self-Management Barriers of Inhalation Corticosteroids in Asthma. <i>Frontiers in Pharmacology</i> , 2021, 12, 767092.	1.6	1
351	Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis. <i>Pharmaceuticals</i> , 2022, 15, 4.	1.7	1
352	Pharmacogenetics: optimising prescribing in primary care. <i>The Prescriber</i> , 2022, 33, 10-13.	0.1	1
353	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. <i>Cancers</i> , 2022, 14, 2838.	1.7	1
354	Pharmacogenetics in the future treatment of rheumatology. <i>Future Rheumatology</i> , 2007, 2, 337-339.	0.2	0
355	Reply to R. Ferraldeschi et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e586-e586.	0.8	0
356	Response: Limited sampling strategies for once daily tacrolimus exposure monitoring. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 775-776.	0.8	0
357	Generation of GMP-Grade CMV pp65-Specific CD8+ and CD4+ Donor T Cell Lines for Treatment of CMV Reactivation after Transplantation.. <i>Blood</i> , 2006, 108, 2931-2931.	0.6	0
358	Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation. <i>Blood</i> , 2008, 112, 3904-3904.	0.6	0
359	Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10518-10518.	0.8	0
360	Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction.. <i>Journal of Clinical Oncology</i> , 2013, 31, 594-594.	0.8	0

#	ARTICLE	IF	CITATIONS
361	The influence of gastrointestinal resection on sunitinib exposure in GIST patients.. Journal of Clinical Oncology, 2013, 31, 10547-10547.	0.8	0
362	Safety and efficacy of the addition of simvastatin to panitumumab in <i>KRAS</i> mutant metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2013, 31, e14558-e14558.	0.8	0
363	Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.. Journal of Clinical Oncology, 2013, 31, 595-595.	0.8	0
364	CYP2D6 genotype related to tamoxifen efficacy: An analysis with exclusion of potential false CYP2D6 genotype assignment caused by loss of heterozygosity in tumor tissue.. Journal of Clinical Oncology, 2013, 31, 597-597.	0.8	0
365	Safety and efficacy of the addition of simvastatin to cetuximab in <i>KRAS</i> mutant metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2013, 31, e14586-e14586.	0.8	0
366	Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival.. Journal of Clinical Oncology, 2014, 32, 11074-11074.	0.8	0
367	Treosulfan-Based Conditioning in Pediatric Hematopoietic Stem Cell Transplantation: A Prospective Study on Pharmacokinetics and Early Clinical Outcomes. Blood, 2014, 124, 3865-3865.	0.6	0
368	<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 4548-4548.	0.8	0